Loading...
•
Jun 30, 2023
Arrowhead Pharmaceuticals Q3 2023 Earnings Report
Arrowhead Pharmaceuticals reported financial results for its fiscal third quarter ended June 30, 2023.
Key Takeaways
Arrowhead Pharmaceuticals reported a net loss attributable to Arrowhead Pharmaceuticals, Inc. of $102.946 million, or $0.96 per share, for the fiscal third quarter ended June 30, 2023. Revenue for the quarter was $15.825 million.
New Phase 1 clinical data on ARO-RAGE showed a continued dose response in healthy volunteers with a single inhaled dose of 184 mg achieving mean knockdown of 90% and a maximum of 95% in bronchoalveolar lavage fluid (BALF).
Completed enrollment of the global PALISADE Phase 3 clinical trial evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome; primary portion of the study is anticipated to be complete in the second quarter of 2024.
Earned a $30 million milestone payment from GSK following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD.
Earned a $40 million milestone payment from Takeda after the first patient was dosed in the Phase 3 REDWOOD clinical study of fazirsiran.
Forward Guidance
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...